Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D.W. Miles; Sanne Lysbet de Haas; Luc Dirix; Gilles Romieu; Arlene Chan

doi:10.1038/bjc.2013.69

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D.W. Miles, Sanne Lysbet de Haas, Luc Dirix, Gilles Romieu, Arlene Chan, Xavier Pivot, Piotr Tomczak, Louise Provencher, Javier Cortés, Paul Delmar, S.J. Scherer

Springer Nature (2013) • Volume 108, Issue 5, Pages 1052-1060

PDF Available

Abstract

Plasma VEGF-A and VEGFR-2 are potential predictive markers for bevacizumab efficacy, supporting findings in gastric and pancreatic cancers. Plasma VEGF-A is being evaluated prospectively in mBC in the MERiDiAN trial.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1038/bjc.2013.69

Language

English

Topic

Cancer Treatment and Pharmacology

Keywords

Bevacizumab, Metastatic breast cancer, Medicine, Docetaxel, Breast cancer, Internal medicine, Oncology, Biomarker, Cancer, Pathology, Chemotherapy, Biology

Published

February 19, 2013

Citations

153 citations

FWCI

14.47

External Resources

DOI Link OpenAlex

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

European guideline for the diagnosis and treatment of insomnia

ChatGPT Utility in Healthcare Education, Research, and Practice: Systematic Review on the Promising Perspectives and Valid Concerns

Interaction of Huntingtin-Associated Protein with Dynactin P150<sup>Glued</sup>

Suggested Papers

Suggested Papers

European guideline for the diagnosis and treatment of insomnia

ChatGPT Utility in Healthcare Education, Research, and Practice: Systematic Review on the Promising Perspectives and Valid Concerns

Interaction of Huntingtin-Associated Protein with Dynactin P150<sup>Glued</sup>